Differential binding mode of diverse cyclooxygenase inhibitors

被引:78
作者
Llorens, O
Perez, JJ
Palomer, A
Mauleon, D
机构
[1] ETSEIB, UPC, Dept Enginyeria Quim, Barcelona 08028, Spain
[2] Labs Menarini, Badalona 08912, Spain
[3] Ferrer Int SA, Barcelona 08028, Spain
关键词
cyclooxygenase docking; NSAIDs; molecular modeling; AMBER;
D O I
10.1016/S1093-3263(01)00135-8
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Non-steroideal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid. There are at least two different isoforms of the enzyme known as COX-1 and -2. Site directed mutagenesis studies suggest that non-selective COX inhibitors of diverse chemical families exhibit differential binding modes to the two isozymes. These results cannot clearly be explained from the sole analysis of the crystal structures of COX available from X-ray diffraction studies. With the aim to elucidate the structural features governing the differential inhibitory binding behavior of these inhibitors, molecular modeling studies were undertaken to generate atomic models compatible with the experimental data available. Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program. The results of the present study provide new insights into a better understanding of the differential binding mode of diverse families of COX inhibitors, and are expected to contribute to the design of new selective compounds. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:359 / 371
页数:13
相关论文
共 44 条
[1]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[2]   Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1 [J].
Bhattacharyya, DK ;
Lecomte, M ;
Rieke, CJ ;
Garavito, RM ;
Smith, WL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (04) :2179-2184
[3]  
CABRE F, UNPUB
[4]  
DeWitt DL, 1999, MOL PHARMACOL, V55, P625
[5]   Comparative molecular modeling study of the three-dimensional structures of prostaglandin endoperoxide H2 synthase 1 and 2 (COX-1 and COX-2) [J].
Filizola, M ;
Perez, JJ ;
Palomer, A ;
Mauleón, D .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 1997, 15 (05) :290-300
[6]  
FRISCH MJ, 1995, GAUSSIAN94 REVISION
[7]   A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors [J].
Gierse, JK ;
McDonald, JJ ;
Hauser, SD ;
Rangwala, SH ;
Koboldt, CM ;
Seibert, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (26) :15810-15814
[9]   The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs [J].
Greig, GM ;
Francis, DA ;
Falgueyret, JP ;
Ouellet, M ;
Percival, MD ;
Roy, P ;
Bayly, C ;
Mancini, JA ;
ONeill, GP .
MOLECULAR PHARMACOLOGY, 1997, 52 (05) :829-838
[10]  
Griswold DE, 1996, MED RES REV, V16, P181, DOI 10.1002/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.0.CO